Immunotherapy Added to Standard Treatment Shows Early Promise Against Aggressive Brain Tumors

High-grade gliomas, the most lethal family of primary brain tumors in adults, have stubbornly resisted nearly every therapeutic innovation of the past two decades. Even with maximal safe surgical resection followed by the standard combination of radiation therapy and the chemotherapy drug temozolomide, the five-year survival rate for patients with these World Health Organization grade III and IV tumors remains below five percent. Against that bleak backdrop, a new retrospective observational study from Beijing Fengtai You’anmen Hospital offers a cautious but noteworthy signal: when a humanized antibody targeting the programmed death receptor 1, known as pucotenlimab, was layered onto concurrent radiochemotherapy, patients showed measurable tumor responses and a disease control rate that reached 92 percent of the treated cohort.

The study, published in BMC Cancer, analyzed 25 adults with histologically confirmed high-grade gliomas who received the triple combination at You’anmen Hospital between April 2023 and October 2025. Because the analysis was retrospective and conducted at a single institution, the investigators themselves frame the findings as preliminary. Yet the numbers are striking enough to attract attention from a field that has repeatedly watched immunotherapy fail in brain cancer. The objective response rate, the proportion of patients whose tumors shrank measurably on imaging, was 36 percent, meaning nine of the 25 patients achieved a response. Disease control, which includes both responses and stable disease, was achieved in 23 of the 25 cases.

Survival outcomes provided the second key signal. Median progression-free survival, the average time patients lived before their tumors began growing again, was 9.4 months. Median overall survival reached 15.2 months. For context, patients with glioblastoma, the most common and aggressive grade IV glioma, treated with the historic Stupp regimen of radiotherapy plus temozolomide typically show median overall survival in the range of 14 to 16 months in clinical trials, with real-world figures often lower. The comparison is far from definitive given the small, uncontrolled, retrospective design, but the fact that adding an immune checkpoint inhibitor did not appear to shorten survival, and may have extended it, is precisely the kind of early signal that justifies larger prospective trials.

Perhaps the most intriguing detail concerns tumor location. Roughly 32 percent of the cases in the cohort involved brainstem lesions, among the most surgically inaccessible and therapeutically challenging sites in neuro-oncology. Responses were observed across different tumor locations, including these difficult brainstem tumors. Any evidence of activity in brainstem high-grade gliomas is notable because treatment options for these patients are extremely limited and clinical trial enrollment is often restricted by the fragility of the anatomic region and the risks of biopsy and resection.

To understand why these results matter, it helps to consider why immunotherapy has struggled in gliomas at all. Immune checkpoint inhibitors such as anti-PD-1 antibodies work by releasing a molecular brake on T cells, the immune system’s cytotoxic soldiers. The PD-1 receptor on T cells binds to its ligands, PD-L1 and PD-L2, on tumor and immune cells, transmitting an inhibitory signal that dampens immune attack. Blocking that interaction with antibodies like pucotenlimab reinvigorates T cells that recognize tumor antigens. This mechanism has transformed the treatment of melanoma, lung cancer, and many other malignancies, but the brain presents a uniquely hostile environment for the approach.

Several barriers explain that history. The blood-brain barrier, and its tumor-modified counterpart the blood-tumor barrier, restricts the passage of large molecules, including antibodies, into the central nervous system. Gliomas are also characterized by low mutation burdens compared with highly immunogenic tumors like melanoma, meaning they present fewer recognizable targets to the immune system. The glioma tumor microenvironment is profoundly immunosuppressive, populated by regulatory T cells, tumor-associated macrophages skewed toward pro-tumor phenotypes, and inhibitory cytokines. In addition, corticosteroids, which patients with brain tumors frequently require to control edema, further suppress immune activity. Finally, earlier randomized trials of anti-PD-1 agents such as nivolumab in newly diagnosed and recurrent glioblastoma failed to improve survival, dampening enthusiasm for the class in this disease.

The rationale for combining a PD-1 inhibitor with radiochemotherapy, rather than testing immunotherapy alone, rests on the concept of immunogenic modulation. Radiation therapy can kill tumor cells in ways that release tumor antigens and upregulate MHC class I molecules, the cellular display platforms that present antigens to T cells, a phenomenon sometimes described as an in-situ vaccine effect. Temozolomide, an alkylating agent that damages DNA, may similarly promote antigen release and lymphocyte priming, although it can also deplete lymphocytes and has been hypothesized in some settings to blunt immunotherapy. The timing of the two modalities relative to checkpoint blockade is therefore a subject of intense investigation, and the concurrent approach used in the You’anmen study, delivering the antibody alongside radiation and chemotherapy rather than after them, is one of several strategies being explored to exploit radiation-induced immune priming.

Safety was the third pillar of the study’s findings. The authors report that the safety profile was favorable and indicated good tolerance of the regimen, with treatment-related adverse events assessed as part of the secondary endpoints. This matters because the standard radiochemotherapy backbone for high-grade glioma already produces predictable toxicities, including bone marrow suppression, fatigue, and radiation-related effects, and because immune-related adverse events from checkpoint inhibitors, such as pneumonitis, colitis, hepatitis, and endocrinopathies, can be difficult to distinguish from tumor progression on brain imaging. A regimen that adds an immunotherapy without an apparent surge of overlapping toxicity is more feasible to test at scale, though the retrospective nature of the safety assessment means the data should be interpreted with corresponding caution.

The study’s limitations are substantial and the authors acknowledge them. With 25 patients treated at a single center, selection bias is a real concern; physicians may have chosen patients with better performance status or more favorable disease characteristics to receive the experimental combination. The absence of a concurrent control group means the response and survival figures cannot be attributed to pucotenlimab with confidence, since historical outcomes vary widely across glioma subtypes, molecular profiles such as MGMT promoter methylation status, and IDH mutation status, all of which powerfully influence prognosis. The retrospective design also precludes standardized imaging review and uniform toxicity grading in the way a prospective trial would mandate. Ethics approval was granted by the You’anmen Hospital Ethics Committee in accordance with the Declaration of Helsinki, with the informed consent requirement waived by the institutional review board because no identifiable patient data were published.

What the study ultimately provides is a hypothesis worth testing rather than a practice-changing result. The investigators conclude that pucotenlimab combined with radiochemotherapy demonstrates preliminary antitumor activity in high-grade gliomas and warrants further prospective validation. For a disease in which the therapeutic arsenal has barely expanded since temozolomide entered standard care in 2005, even a preliminary signal of a 36 percent response rate and 92 percent disease control is enough to energize the field. The next step, and the one that will determine whether this approach reaches patients, is a properly powered, multi-center, prospective randomized trial with molecular stratification, blinded independent imaging review, and rigorous immune-related toxicity monitoring. Until such data arrive, the Beijing results stand as an early, cautiously encouraging chapter in the long effort to make brain cancers vulnerable to immunotherapy.

Subject of Research: Evaluation of pucotenlimab combined with concurrent radiochemotherapy in adult high-grade gliomas

Article Title: Preliminary evaluation of concurrent radiochemotherapy plus pucotenlimab in adult high-grade gliomas: a single-institution retrospective observational study

Article References: Yang, H., Shen, G., Sun, Q.-Y., Yao, Z.-Y., Liu, C., Li, N., Yang, G., Wang, K.-P., & Da, Y. (2026). Preliminary evaluation of concurrent radiochemotherapy plus pucotenlimab in adult high-grade gliomas: a single-institution retrospective observational study. BMC Cancer. https://doi.org/10.1186/s12885-026-17154-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17154-0

Keywords: high-grade glioma, glioblastoma, pucotenlimab, PD-1 inhibitor, radiochemotherapy, temozolomide, immunotherapy, blood-brain barrier, progression-free survival, overall survival, brainstem glioma, retrospective study